Actavia Life Sciences, Inc.
RASP · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $2 |
| Gross Profit | $0 | $0 | -$0 | -$2 |
| % Margin | – | – | – | – |
| R&D Expenses | $92 | $84 | $55 | $0 |
| G&A Expenses | $287 | $300 | $193 | $557 |
| SG&A Expenses | $287 | $300 | $193 | $557 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3,858 | $0 | $0 | $0 |
| Operating Expenses | $4,238 | $384 | $248 | $557 |
| Operating Income | -$4,238 | $141 | -$248 | -$5,429 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$204 | -$828 | -$628 | $79 |
| Pre-Tax Income | -$4,443 | -$687 | -$876 | -$5,350 |
| Tax Expense | $0 | $0 | $0 | -$3 |
| Net Income | -$4,443 | -$687 | -$876 | -$5,347 |
| % Margin | – | – | – | – |
| EPS | -0.008 | -0.01 | -0.013 | -0.078 |
| % Growth | 23% | 21.3% | 83.6% | – |
| EPS Diluted | -0.008 | -0.006 | -0.013 | -0.078 |
| Weighted Avg Shares Out | 578,017 | 68,658 | 68,908 | 68,908 |
| Weighted Avg Shares Out Dil | 578,017 | 111,426 | 68,908 | 68,908 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $213 | $941 | $516 | $41 |
| Depreciation & Amortization | $3,850 | $0 | $0 | $2 |
| EBITDA | -$380 | $255 | -$247 | -$555 |
| % Margin | – | – | – | – |